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1. Introduction 
Cancer has been previously viewed as a disease exclusively driven by genetic changes, 
including mutations in tumor suppressor genes and oncogenes, and chromosomal 
abnormalities. However, recent data have demonstrated that the complexity of human 
carcinogenesis cannot be accounted for by only genetic machineries, but also involves 
extensive epigenetic abnormalities. The term “epigenetics” refers to the study of heritable 
changes in gene regulation that do not involve a change in the DNA sequence or the 
sequence of the proteins associated with DNA (Egger et al. 2004). Epigenetic machineries 
plays a fundamental role in several biological processes, such as embryogenesis, imprinting, 
and X chromosome inactivation, and in disease states such as cancer. Several mechanisms 
were included in the epigenetic machinery, the most studied of which are DNA 
methylation; histone modifications; and small, noncoding RNAs (Kargul and Laurent 2009; 
Jeltsch and Fischle 2011). The molecular mechanisms underlie the epigenetic changes in 
cancer cells are complicate and only began to be elucidated. The best understood component 
among which is the transcriptional repression of a growing list of tumor suppressor and 
candidate tumor suppressor genes (Jones and Laird 1999; Esteller 2007). This suppression is 
associated with abnormal methylation of DNA at certain CpG islands that often lie in the 
promoter regions of these genes (Esteller 2006, 2007). 
Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer with remarkably 
distinctive ethnic and geographic distribution among the world. The three major etiologic 
factors of NPC were well defined as genetic susceptibility, environmental factors and latent 
infection of the Epstein-Barr Virus (EBV) (Tao and Chan 2007; Lo, To, and Huang 2004). 
During the passing decade, much attention has been paid to the role of epigenetic 
alternations occurred in the procedure of tumorigenesis of NPC (Li, Shu, et al. 2011; Tao and 
Chan 2007).  
In this chapter, we will first describe the general mechanisms through which the epigenetic 
alternations in cancer, then focus on the epigenetic alterations taking place in NPC, with an 
emphasis on DNA methylation. 
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2. DNA methylation, histone modifications and chromatin structure 
DNA methylation is the only genetically programmed DNA modification in mammals. This 
postreplication modification is almost exclusively found on the 5′ position of the pyrimidine 
ring of cytosines in the context of the dinucleotide sequence CpG. 5′-methylcytosine 
accounts for ∼1% of all bases, varying slightly in different tissue types and the majority 
(75%) of CpG dinucleotides throughout mammalian genomes are methylated (Tost 2010). 
Sequence regions with a high density of CpG residues are termed as CpG islands. A CpG 
island is defined as a sequence of 200-plus base pairs with a G+C content of more than 50%, 
and an observed versus expected ratio for the occurrence of CpGs of more than 0.6 (Jones 
and Takai 2001). These CpG islands are associated with gene promoters in approximately 
50% of genes and are generally maintained in an unmethylated state. DNA methylation can 
interfere with transcription in several ways. It can inhibit the binding of transcriptional 
activators with their cognate DNA recognition sequence such as Sp1 and Myc through 
sterical hindrance. The methylation binding proteins and the DNA methyltransferases 
(DNMTs) bind to methylated DNA and prevent the binding of potentially activating 
transcription factors. The methylation binding proteins and DNMTs also recruit additional 
proteins with repressive function such as histone deacetylases and chromatin remodeling 
complexes to the methylated DNA to establish a repressive chromatin configuration (Bird 
2002). 
To date, three major cellular enzymic activities associated with DNA methylation have been 
characterized (DNMT1, DNMT3A, and DNMT3B) (Malik and Brown 2000). They catalyze 
the transfer of a methyl group from SAM to the cytosine base. DNMT1 is considered as a 
maintenance methyltransferase, it is located at the replication fork during the S phase of the 
cell cycle and catalyze the methylation of the newly synthesized DNA strand using the 
parent strand as a template. The methyltransferases DNMT3A and DNMT3B are responsible 
for De novo methylation. These enzymes not only targeting specific sequences, they also 
work cooperatively to methylate the genome (Malik and Brown 2000).  
Tumor-specific elevation of DNMTs is a causative step in many cancers. All three DNMTs, 
were observed modestly overexpressed in many types of tumor cells at the mRNA or 
protein level (Robertson et al. 1999). Furthermore, modest overexpression of exogenous 
mouse Dnmt1 in NIH 3T3 cells can promote cellular transformation (Wu et al. 1993). 
Additionally, genetic inactivation of Dnmt1 in mice decreases the development of 
gastrointestinal tumors in a mouse model of gastrointestinal cancer (Laird et al. 1995). These 
evidences indicate a possible role for DNMTs in tumorigenesis. However, the mechanisms 
that underlie such a role in cancer are still not defined. 
Genomic DNA is highly folded and packaged into chromosomes or chromatin by histone 
and nonhistone proteins in the nuclei of all eukaryotic cells (Jenuwein and Allis 2001). The 
fundamental repeating unit of chromatin is the nucleosome, in which 146 DNA base pairs 
are wrapped left handed around a core histone protein, which consists of two of each of the 
four histone protein subunits: H2A, H2B, H3 and H4. Each core histone has an amino-
terminal 'tail' of about 25-40 residues long, where they are frequent targets for various 
posttranslational modifications (Fischle, Wang, and Allis 2003). The state of chromatin is 
regulated largely by covalent modifications of the histone tails. The major modifications 
include the acetylation of specific lysine residues by histone acetyltransferases (HATs), the 
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methylation of lysine and arginine residues by histone methyltransferases (HMTs), and the 
phosphorylation of specific serine groups by histone kinases (HKs). Other histone 
modifications include attachment of ubiquitination, and sulmolation. Enzymes responsible 
for the cleavage of some histone modifications, such as histone deacetylases (HDACs), 
histone phosphatases (PPs), ubiquitin hydrolases (Ubps) and poly (ADP-
ribose)glycohydrolases (PARGs), have already been identified (Biel, Wascholowski, and 
Giannis 2005). 
Posttranslational modifications are closely related to fundamental cellular events like the 
activation and repression of transcription. In the case of histone H3, in general, acetylation 
of H3 at lysine 14 (H3-K14), phosphorylation of serine 10 (H3-S10), and methylation of 
H3-K4 leads to transcriptional activation. In contrast, the repression of certain genes is 
linked to deacetylation of H3-K14 and methylation of H3-K9. The specific combination of 
these modifications has been termed the histone code, that determines histone–DNA and 
histone–histone contacts, which may in turn regulate the on or off state of genes or 
unfolding/folding state of the chromatin structure (Jenuwein and Allis 2001; Esteller 
2007).  
Histone modifications and other epigenetic mechanisms such as DNA methylation appear 
to work together in a coordinated and orderly fashion, to establishing and maintaining gene 
activity states, thus regulating gene transcription (Fischle, Wang, and Allis 2003; Biel, 
Wascholowski, and Giannis 2005). In the past decade, more and more attention has been 
paid on histone modifications, which led to the discovery and characterization of a large 
number of histone-modifying molecules and protein complexes. Alterations of histone-
modifying complexes are believed to disrupt the pattern and levels of histone marks and 
consequently dysregulate the normal control of chromatin-based cellular processes, 
ultimately leading to oncogenic transformation and the development of cancer (Esteller 
2007). 
3. NPC as an epigenetic disease 
3.1 Hypermethylation of cellular tumor suppressor genes and the dysregulation of the 
corresponding cellular pathways 
NPC distinguish itself from other malignancies by the number of genes targeted for 
silencing by promoter methylation. Several classic tumor suppressor genes, such as p53 and 
Rb, are found to be mutated in more than 50% of all the tumors, but were rarely found to be 
mutated in NPC (Burgos 2003; Chang et al. 2002; Tao and Chan 2007). On the contrary, 
hypermethylation of known or candidate tumor suppressor genes involved in various 
fundamental pathways has been reported in NPC, such as apoptosis, DNA damage repair, 
tumor invasion and metastasis. The full list of genes which have been found to be aberrantly 
methylated in NPC was summarized in table 1. 
Ras signalling 
Activated Ras proteins has been shown to play a key role in the development of human 
cancers (Bos 1989). Ras proteins serve as a node in the transduction of information from a 
variety of cell surface receptors to an array of intracellular signaling pathways. Mutated 
variants of Ras (mutations at residues 12, 13 or 61) are found in 30% of all human cancers 
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(Bos 1989). Mutations at residues 12, 13 or 61 might lock Ras protein in the active state, 
which mediate a variety of biological effects associated with enhanced growth and 
transformation. Ras activity is regulated by cycling between inactive GDP-bound and active 
GTP-bound forms. When GTP-bound, Ras binds to and activates a plethora of effector 
molecules. GTPase-activating proteins (GAPs), such as p120GAP and NF1, trigger the 
hydrolysis of GTP back to the inactive GDP-bound form (Boguski and McCormick 1993). 
Because Ras GAPs switch off Ras signalling, they have always been considered as potential 
tumor suppressor genes. Recent study reveal that the Ras GTPase-activating-like protein 
(RASAL), a Ca2+-regulated Ras GAP that decodes the frequency of Ca2+ oscillations, is 
silenced through CpG methylation in multiple tumors including NPC (Jin, Wang, Ying, 
Wong, Cui, et al. 2007). In addition, ectopic expression of catalytically active RASAL leads to 
growth inhibition of NPC cells by Ras inactivation, thus, epigenetically silencing of RASAL 
is an alternative mechanism of aberrant Ras activation in NPC (Jin, Wang, Ying, Wong, Cui, 
et al. 2007). 
Although it is widely accepted that Ras functions as an oncoprotein, more and more 
evidence show that Ras proteins may also induces growth arrest properties of cells, such as 
senescence, apoptosis, terminal differentiation (Spandidos et al. 2002). The growth 
inhibitory effects of Ras were induced by a group of proteins with Ras binding domain. 
These proteins were identified as negative effectors of Ras and designated as Ras association 
domain family (RASSF). Within this super family, the RASSF1A and RASSF2A gene are 
frequently inactivated by promoter hypermethylation (Lo et al. 2001; Zhang et al. 2007), 
functional studies also support their role as putative tumor suppressors in NPC.  
The induction of invasiveness and metastasis by Ras were mediated by downstream 
effectors which are involved in the regulation of cell adhesion, cell-matrix interaction and 
cell motility, such as RhoGTPases, RalGEF and components of PI3K pathways (Giehl 2005). 
Recent studies have further indicated that the Ras/PI3K/AKT pathway is associated in 
several human cancers. Activation of the Ras/PI3K/AKT pathway can occur by many 
mechanisms, which include activation of Ras, mutation or amplification of PI3K, 
amplification of AKT, and mutation/decreased expression of the tumor-suppressor genes 
PTEN and HIN-1. The HIN-1 gene has various biological functions, including inhibiting cell 
cycle reentry, suppressing migration and invasion, and inducing apoptosis; these effects are 
mediated by inhibiting AKT signalling pathway (Krop et al. 2005). HIN-1 gene is 
hypermethylated in human NPC. Methylated HIN-1 promoter was found in 77% of primary 
NPC tumors and not found in the normal nasopharyngeal biopsies. Moreover, methylated 
HIN-1 promoter can be detected in 46% of nasopharyngeal swabs, 19% of throat-rinsing 
fluids, 18% of plasmas, and 46% of buffy coats of peripheral blood of the NPC patients but 
was not detectable in all normal controls (Wong, Kwong, et al. 2003). 
The Ras family shares at least 30% sequence identity with several other small monomeric G 
protein families, such as the Rho/Rac/CDC42, Rab/Ypt, Ran, Arf, and Rad families (Adjei 
2001). The major 8p22 tumor suppressor Deleted in Liver Cancer 1 (DLC1) gene is a 
homologue of rat p122RhoGAP. It was identified as a major downregulated gene in NPC by 
expression subtraction. By expression subtraction, Qian Tao’s group identified that DLC1 is 
an 8p22 TSG as a major downregulated gene in NPC. Their study also demonstrated DLC1 
is hypermethylated not only in NPC, but also in esophageal and cervical 
carcinomas. Downregulation of DLC1 contributes to NPC oncogenesis by disrupting 
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Ras-mediated signalling pathways (Seng et al. 2007). Recently, a novel isoform of the DLC1 
gene was identified, which suppresses tumor growth and frequently silenced in multiple 
common tumors including NPC. This novel isoform encodes an 1125-aa (amino acid) 
protein with distinct N-terminus as compared with other known DLC1 isoforms. Similar to 
other isoforms, DLC1-i4 is expressed ubiquitously in normal tissues, and epigenetically 
inactivated by promoter hypermethylation in NPC. The differential expression of various 
DLC1 isoforms suggests interplay in modulating the complex activities of DLC1 during 
carcinogenesis (Low et al. 2011).  
P53 signalling  
Altered p53 pathway is common detected in NPC, even though NPC rarely presents 
abnormality in the p53 gene itself, p53 function may be inactivated by either overexpression 
of ΔN-p63 or loss of p14/ARF. ΔN-p63 is a p53 homolog. It can block p53’s function as 
transcription factor. P14 functions as a stabilizer of p53 as it can interact with, and sequester, 
MDM1, a protein responsible for the degradation of p53 (Ozenne et al. 2010). p14 is 
methylated in 20% on NPC, the epigenetic inactivation of p14/ARF may facilitate p53 
degradation in NPC cells (Kwong et al. 2002). Loss of p53 function may affect cell cycle 
arrest at the G1 or G2/M phase and p53-mediated apoptosis in response to DNA damage 
(Kwong et al. 2002; Crook et al. 2000).  
Recently, Qian Tao et al. found that UCHL1 was frequently silenced by promoter CpG 
methylation in nasopharyngeal carcinoma; and acts as a functional tumor suppressor gene 
for NPC through stabilizing p53 through deubiquitinating p53 and p14ARF and 
ubiquitinating MDM2, which is mediated by its hydrolase and ligase activities, further 
resulting in the induction of tumor cell apoptosis (Li et al. 2010).  
Wnt signalling  
The Wnt signalling pathway is important for normal development and is frequently 
aberrantly activated in a variety of cancers. Although the role of the Wnt pathway in NPC 
has not been fully explored, there is abundant evidence that aberrant Wnt signalling plays a 
role in NPC development. In a recent study by gene expression profiling, the aberrant 
expression of the Wnt signalling pathway components, such as wingless-type MMTV 
integration site family, member 5A, Frizzled homolog 7, casein kinase II beta, ǃ-catenin, 
CREB-binding protein, and dishevelled-associated activator of morphogenesis 2 was 
identified and further validated on NPC tissue microarrays (Zeng et al. 2007). Furthermore, 
most NPC tumors exhibit Wnt pathway protein dysregulation: 93% have increased Wnt 
protein expression and 75% have decreased expression of Wnt inhibitory factor (WIF), an 
endogenous Wnt antagonist (Shi et al. 2006; Zeng et al. 2007). These results indicate that 
aberrant Wnt signalling is a critical component of NPC. 
The Wnt inhibitory factor 1 (WIF1) gene acts as a Wnt antagonist factor by direct binding to 
Wnt ligands. In NPC, methylation was frequently observed in 85% of NPC primary tumors, 
with WIF1 expressed and unmethylated in normal cell lines and normal tissues. Ectopic 
expression of WIF1 in NPC cells resulted in significant inhibition of tumor cell colony 
formation, and significant downregulation of ǃ-catenin protein level in NPC cells. Indicates 
that epigenetic inactivation of WIF1 contributes to the aberrant activation of Wnt pathway 
and is involved in the pathogenesis of NPC (Chan et al. 2007). 
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Cell cycle and DNA repair 
Aberrant apoptosis, as in all malignancies, is also required for NPC development. Inhibition 
of apoptosis seems to be critical to NPC tumorigenesis. Death-associated protein kinase 
(DAPK) is a Ca/calmodulin-regulated serine/threonine kinase and a positive mediator of 
apoptosis. Loss of DAPK expression was shown to be associated with promoter region 
methylation in NPC. Methylation of the promoter was found in 76% of NPC, as well 
as plasma of patients with NPC (Chang et al. 2003). A demethylating agent, 5-aza-2'-
deoxycytidine, might slow the growth of NPC cells in vitro and in vivo by reactivating the 
DAPK gene silenced by de novo methylation (Kong et al. 2006). 
Like all cancers, development of NPC requires the derangement of the normal cell cycle. 
Several classical CDK inhibitors in G1 -S checkpoint, such as p16/INK4A, p15/INK4A, 
and p14/ARF, were demonstrated to be hypermethylated in NPC and act as tumor 
suppressors during NPC development (Li, Shu, et al. 2011).  
Dysregulation of the DNA repair system by DNA methylation is also an essential event in 
NPC development (Lo, To, and Huang 2004; Tao and Chan 2007). MGMT is a DNA repair 
protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Frequent 
methylation of MGMT associated with gene silencing occurs in human cancers. However, 
only a small portion (28%) of primary NPC were MGMT hypermethylated (Wong, Tang, et 
al. 2003). A rather high frequency (40%) of hypermethylation of the DNA mismatch repair 
gene hMLH1 was observed in NPC primary tumors (Wong, Tang, et al. 2003). But 
methylation of hMLH1 cannot be detected in the plasma of NPC patients (Wong et al. 2004).  
Chromosomal instability (CIN) is a cytogenetic hallmark of human cancers (Cheung et al. 
2005; Lengauer, Kinzler, and Vogelstein 1998). Increasing evidence suggests that 
impairment of mitotic checkpoint is causally associated with CIN. Several chromosomal 
aberrations have been identified in NPC. Some sites correspond to proteins key to NPC 
development, including p16, RASSF1A, and CKIs, while a number of sites do not 
correspond to any known tumor suppressors or oncogenes (Li, Shu, et al. 2011). CHFR is 
one of the mitotic checkpoint regulators and it delays chromosome condensation in 
response to mitotic stress. CHFR mRNA was significantly decreased or undetectable in NPC 
cell lines as well as human NPC xenografts, hypermethylation of CHFR promoter was 
strongly correlated with decreased CHFR expression in NPC cell lines and xenografts 
(Cheung et al. 2005). And hypermethylation of CHFR promoter region was detected in 
61.1% (22 out of 36) of primary NPC tumors while it was absent in non-malignant tissues 
(Cheung et al. 2005). 
Cell adhesion 
Multiple cell adhesion molecules involve in intercellular and cell-extracellular matrix 
interactions of cancer. Cancer progression is a multi-step process in which some adhesion 
molecules play a pivotal role in the development of recurrent, invasion, and metastasis. 
Alterations in the adhesion properties of cancer cells play an essential role in the 
development and progression of cancer. Loss of intercellular adhesion allows malignant 
cells to escape from their site of origin, degrade the extracellular matrix, acquire a more 
motile and invasion phenotype, and finally, invade and metastasize. In NPC, epigenetic 
mechanism was involved in the abnormal cell adhesion, a diverse of molecules such as 
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cadherins, connexins, and other components of cell adhesion are dysregulated (Du et al. 
2011; Sun et al. 2007; Ying et al. 2006; Huang et al. 2001; Lou, Chen, Lin, et al. 1999; Xiang et 
al. 2002). 
Cadherins have strong implications in tumorigenesis through cadherin-mediated cell–cell 
adhesion, which maintains tissue integrity and homeostasis. Disruption of this organized 
adhesion by genetic and epigenetic mechanisms during carcinogenesis might result in 
changes in signal transduction, loss of contact inhibition, and altered cell migration and 
stromal interactions. Some of the cadherins, such as E-cadherin and H-cadherin, were 
characterized as TGSs, which inhibit tumor invasion and metastasis (Berx and van Roy 2009; 
Jeanes, Gottardi, and Yap 2008). Disruption of cadherin expression and inappropriate 
switching among cadherin family members by genetic or epigenetic mechanisms are key 
events in the acquisition of the invasive phenotype for many tumors. The E-cadherin gene is 
silenced by promoter hypermethylation in human NPC because of aberrant expression of 
DNMT induced by the Epstein-Barr virus-encoded oncoprotein latent membrane 1 (Tsai et 
al. 2002). Moreover, loss of E-cadherin expression is significantly associated with 
histological grade, intracranial invasion and lymph node and distant metastasis (Lou, Chen, 
Sheen, et al. 1999). Three other members of the cadherin family: CDH13, CDH4 and 
PCDH10, are involved in NPC owing to promoter methylation (Sun et al. 2007; Ying et al. 
2006; Du et al. 2011). This evidence indicates a deep involvement of epigenetic regulation of 
the cadherin family in the carcinogenesis of NPC. 
Intercellular communication through gap junction (GJIC) have a significant role in 
maintaining tissue homeostasis and has long been proposed as a mechanism to regulate 
growth control, development and differentiation. Reduced GJIC activity has long been 
implicated in carcinogenesis. Loss of GJIC leads to aberrant proliferation and an enhanced 
neoplastic phenotype. Reduced expression of the connexin (Cx) genes dysregulation of GJIC 
activity were observed in a series of human cancers. Thus, some Cx genes have been 
suggested as tumor suppressor genes (Pointis et al. 2007). Down-regulation of connexin 43 
(Cx43) expression and dysfunctional GJIC were demonstrated in NPC tissues and cells, 
suggesting that dysfunctional GJIC plays a key role in nasopharyngeal carcinogenesis (Shen 
et al. 2002; Xiang et al. 2002). Further study revealed that inactivation of Cx43 gene was 
mediated by epigenetic mechanism of promoter hypermethylation in NPC. Treatment of 
DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine could induce restoration of GJIC 
and an inhibition of tumor phenotype of CNE-1 cells (Yi et al. 2007). 
MMPs are type IV collagenases whose overexpression has been implicated in a number of 
cancers. MMPs can not only degrade basement membranes and extracellular matrices to 
allow for tumor invasion, they are also involved in activation of growth factors to promote 
cell growth and angiogenesis, and also protect tumor cells from apoptotic signals (Gialeli, 
Theocharis, and Karamanos 2011). In NPC, MMP1, MMP3 and MMP9 were shown to be up-
regulated by LMP1 (Stevenson, Charalambous, and Wilson 2005; Kondo et al. 2005; Lee et al. 
2007). While MMP19 appears to be down-regulated in 69.7% of primary NPC specimens 
(Chan et al. 2010). Allelic deletion and promoter hypermethylation contribute to MMP19 
down-regulation. The catalytic activity of MMP19 plays an important role in anti-tumor and 
anti-angiogenesis activities (Chan et al. 2010). 
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OPCML (opioid binding protein/cell adhesion molecule-like gene), also known as OBCAM 
(opioid binding cell adhesion molecule), belonging to the IgLON family of 
glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules involved in cell 
adhesion and cell-cell recognition. Located at 11q25, OPCML was the first IgLON member 
linked to tumorigenesis. In NPC, the OPCML-v1 were observed to be epigenetically 
inactivated, what’s more, the methylation was detected in a remarkable frequency: 98% of 
NPC tumor tissues. The high incidence of epigenetic inactivation of OPCML in NPC 
indicates that OPCML methylation could be an epigenetic biomarker for the molecular 
diagnosis of NPC (Cui et al. 2008). 
 
Cancer-
related 
process 
Gene Full name Chromo-
somal 
location
Function Refs 
Cell cycle CDKN2B/ 
P15/MTS2/T
P15/ 
INK4B 
Cyclin-dependent 
kinase inhibitor 2B
9p21 Cyclin-dependent kinase 
inhibitor for CDK4 and 
CDK6, a cell growth 
regulator of cell cycle  
G1 progression 
 (Wong, Tang,  
et al. 2003; Chang 
et al. 2003; Wong 
et al. 2004; Li, 
Shu, et al. 2011) 
 CDKN2A/ 
P16/INK4A/
MTS1/ 
CDK4I/ 
CDKN2 
Cyclin-dependent 
kinase inhibitor 2A
9p21 Cell cycle regulation  (Wong et al. 
2004; Chang et al. 
2003; Wong, 
Tang, et al. 2003; 
Lo et al. 1996; Li, 
Shu, et al. 2011) 
 CHFR/ 
RNF116/ 
RNF196 
Checkpoint with 
forkhead and ring 
finger domains 
12q24.33 Mitotic checkpoint 
regulator early in  
G2-M transition 
 (Cheung et al. 
2005; Li, Shu, et 
al. 2011) 
 BRD7 Bromodomain 
containing 7 
16q12 Transcriptional regulation, 
inhibits G1-S transition 
 (Liu et al. 2008) 
 FHIT/ 
FRA3B/ 
3P3Aase 
Fragile histidine 
triad gene 
3P14.2 Cell-cycle regulation, G1-S 
phase checkpoint,  
DNA-damage response, 
nucleotide and nucleic acid 
metabolism 
 (Loyo et al. 2011) 
 GADD45G Growth arrest and 
DNA-damage-
inducible, gamma 
 
9q22 Inhibits G1-S and G2-M 
transition, apoptosis 
 (Ying et al. 2005) 
 DLEC1 Deleted in lung 
and esophageal 
cancer1 
 
3p22-
21.3 
G1 cell cycle arrest  (Ayadi et al. 
2008) 
 ZMYND10/
BLU 
Zinc finger， 
MYND-type 
containing 10 
 
3P21.3 Cell cycle  (Liu et al. 2003) 
 MIPOL1 Mirror-image 
polydactyly1 
14q13.1 Negative regulator of  
G1 progression 
 (Cheung  
et al. 2009) 
 PRDM2/ 
PRDM2 
PR domain 
containing 2, 
with ZNF domain 
1p36.21 G2-M cell cycle arrest  (Chang  
et al. 2003) 
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Cancer-
related 
process 
Gene Full name Chromo-
somal 
location
Function Refs 
 LTF Lactoferrin 3p21.3 Cell cycle regulation   (Yi et al. 2006; 
Zhang et al. 2011) 
 CCNA1 Cyclin A1 13q12.3-
q13 
An important regulator of 
the cell cycle required for  
S phase and passage 
through G2 
 (Yanatatsaneejit 
et al. 2008) 
 PTPRG Receptor-type 
tyrosine-protein 
phosphatase 
gamma 
3p14-21 Cell cycle regulator via 
inhibition of pRB 
phosphorylation through 
down-regulation of cyclin 
D1 
 (Cheung  
et al. 2008) 
 TP73 Tumor protein p73 1p36.3 Cell cycle, DNA damage 
response, apoptosis, 
transcription factor 
 (Wong, Tang, et 
al. 2003) 
Apoptosis DAPK Death-associated 
protein kinase 
9p34.1 Positive mediator of 
gamma-interferon induced 
apoptosis 
 (Wong et al. 
2004; Chang et al. 
2003; Kwong et 
al. 2002; Li, Shu, 
et al. 2011) 
 CASP8/CAP
4/MACH/M
CH5/ 
FLICE
Caspase 8, 
apoptosis-related 
cysteine peptidase
2q33-q34 Apoptosis  (Li, Shu, et al. 
2011; Wong, 
Tang, et al. 2003) 
 GSTP1/ 
DFN7/ 
GST3 
Glutathione S-
transferase pi 1 
11q13 Apoptosis, metobolism, 
energy pathways  
 (Kwong et al. 
2002; Li, Shu,  
et al. 2011) 
 CMTM3 CKLF like 
MARVEL 
transmembrane 
domain-containing 
member 3 
16q21 Induces apoptosis with 
caspase-3 activation 
 (Wang et al. 
2009) 
 CMTM5 CKLF like 
MARVEL 
transmembrane 
domain-containing 
member 5 
14q11.2 Induces apoptosis with 
activation of caspase 3,  
8 and 9, synergistic effects 
with TNF-ǂ. 
 (Shao et al. 2007) 
 ZNF382 Zinc finger protein 
382 
19q13.12 Key regulator of cell 
proliferation, 
differentiation, and 
apoptosis, repress NF-kB 
and AP-1 signaling 
(Cheng  
et al. 2010) 
 TNFRSF11B
/OPG 
Tumor necrosis 
factor receptor 
superfamily, 
member 11b 
8q24 Induced apoptosis，inhibits 
tumor growth specifically 
in bones 
 (Lu et al. 2009) 
 PLA2G16/H
RASLS3 
Phospholipase A2, 
group XVI 
11q12.3 Proapoptotic function 
through the inhibition of 
PP2A 
 
 (Yanatatsaneejit 
et al. 2008) 
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Cancer-
related 
process 
Gene Full name Chromo-
somal 
location
Function Refs 
Invasion 
and 
metastasis 
CDH1 Cadherin 1, type 1, 
E-cadherin 
(epithelial) 
16q22.1 Calcium-dependent 
adhesion and cell migration
 (Wong, Tang,  
et al. 2003; Wong 
et al. 2004) 
CDH13 Cadherin 13, H-
cadherin (heart) 
16q23.3 Calcium-dependent 
adhesion and cell migration
 (Sun et al. 2007) 
 PCDH10 
/OL-PCDH 
/KIAA1400 
Protocadherin 10 4q28.3 Calcium-dependent 
adhesion and cell migration
 (Ying et al. 2006) 
 CDH4 Cadherin 4, type 1, 
R-cadherin 
(retinal) 
20q13.3 Calcium-dependent 
adhesion and cell migration
 (Du et al. 2011) 
 OPCML Opioid binding 
protein/cell 
adhesion molecule
11q25 Cell adhesion, cell-cell 
recognition 
 (Cui et al. 2008) 
 TFPI-2 Tissue factor 
pathway inhibitor-
2 
7q22 Serine protease inhibitor  (Wang et al. 
2010) 
 MMP19 Matrix 
metalloproteinase-
19 
12q14 Extra cellular matrix  (Chan et al. 2010) 
 THBS1 Thrombospondin 1 15q15 An adhesive glycoprotein 
that mediates cell-to-cell 
and cell-to-matrix 
interactions 
 (Wong, Tang, et 
al. 2003) 
 Cx43 Connexin 43 20q11 Gap junction and 
intercellular communication
 
 (Yi et al. 2007) 
 TSLC1 
/CADM1 
Tumor suppressor 
in lung cancer 1 
11q23 Cell adhesion molecules, 
mediate cell-cell interaction
 (Hui et al. 2003; 
Lung et al. 2004) 
 ADAMTS18 ADAM 
metallopeptidase 
with 
thrombospondin 
type 1 motif, 18 
16q23.1 Cell adhesion modulator, 
inhibits growth factor-
independent cell 
proliferation 
 (Jin, Wang, Ying, 
Wong, Li, et al. 
2007; Wei et al. 
2010) 
 THY1/CD90 Thy-1 cell surface 
antigen 
11q23.3 Regulates cytoskeletal 
organization, focal adhesion 
and migration by 
modulating the activity  
of p190 RhoGAP and  
Rho GTPase 
 
 (Lung et al. 2005) 
DNA 
repair 
MGMT O-6-
methyoguanine-
DNA 
methyltransferase 
10q26 Repair alkylated guanine  (Kwong  
et al. 2002) 
 MLH1 
/hMLH1 
/HNPCC 
/FCC2 
MutL homolog 1, 
colon cancer, 
nonpolyposis type 
2 (E. coli) 
3p21.3 DNA mismatch repair 
protein, cell cycle  
G2-M arrest 
 (Wong, Tang, et 
al. 2003; Wong et 
al. 2004) 
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Cancer-
related 
process 
Gene Full name Chromo-
somal 
location
Function Refs 
Signal 
transduction 
ARF/P14 Alternate open 
reading frame 
9p21 Stabilizes p53, interacts 
with MDM2 
 (Li, Shu, et al. 
2011; Wong, 
Tang, et al. 2003) 
RASSF1A Ras association 
(RalGDS/AF-6) 
domain family 
member 1A 
3p21.3 Regulate Ras signaling 
pathway 
 (Chow et al. 
2004; Zhou et al. 
2005) 
RASFF2A Ras association 
(RalGDS/AF-6) 
domain family 
member 2A 
20p12.1 Regulate Ras signaling 
pathway 
 (Zhang et al. 
2007) 
WIF-1 Wnt inhibitory 
factor-1 
12q14 Antagonist of Wnt signaling  (Lin et al. 2006; 
Chan et al. 2007) 
DLC-1 Deleted in liver 
cancer-1 
8p21.3-
22 
GTPase-activating protein 
specific for RhoA and 
Cdc42 
 (Peng et al. 2006) 
 DAB2 Disabled homolog 
2, mitogen-
responsive 
phosphoprotein 
(Drosophila) 
5p13 Adaptor molecule involved 
in multiple receptor-
mediated signaling 
pathways 
 (Tong et al. 2010) 
 RASAL1 RAS protein 
activator like 1 
(GAP1 like) 
12q23-
q24 
Ras GTPase-activating 
protein, negatively 
regulates RAS signaling 
 (Jin, Wang, Ying, 
Wong, Cui, et al. 
2007) 
 UCHL1 Ubiquitin 
carboxyl-terminal 
esterase L1 
4p14 Stabilize p53 and activate 
the p14ARF-p53 signaling 
pathway 
 
 (Li et al. 2010) 
 SFN/14-3-3 σ Stratifin 1p36.11 Downstream target of p53, 
negative regulator of  
G2-M phase checkpoint 
 
 (Yi et al. 2009) 
Angio-
genesis 
EDNRB Endothelin 
receptor type B 
13q22 Negative regulator of 
ET/ETAR pathway 
 
 (Lo et al. 2002; 
Zhou et al. 2007) 
ADAMTS9 A disintegrin-like 
and 
metallopeptidase 
with 
thrombospondin 
type 1 motif 9 
 
3p14.1 Anti-angiogenesis  (Lung, Lo, Xie, et 
al. 2008) 
 FBLN2 Fibulin 2 3p25.1 Angiogenesis suppression 
via concomitant 
downregulation of vascular 
endothelial growth  
factor and matrix 
metalloproteinase 2 
 
 (Law et al. 2011) 
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Cancer-
related 
process 
Gene Full name Chromo-
somal 
location
Function Refs 
Vitamin 
response 
RARβ2 Retinoic acid 
receptor beta 2 
3q24 Binds retinoic acid to 
mediates cellular signaling 
during embryonic 
morphogenesis, cell growth 
and differentiation 
 
 (Kwong, Lo, 
Chow, To, et al. 
2005; Kwong et 
al. 2002; Seo, Kim, 
and Jang 2008) 
RARRES1 
/TIG1 
Retinoic acid 
receptor responder 
(tazarotene 
induced) 1 
3q25 Retinoic acid target gene  (Yanatatsaneejit 
et al. 2008; 
Kwong, Lo, 
Chow, Chan, et 
al. 2005; Kwok et 
al. 2009) 
CRBPⅠ 
/RBP1 
Cellular retinol 
binding protein 1 
3q23 Draws retinol from blood 
stream into cells, solubilizes 
retinol and retinal, protects 
cells from membranolytic 
retinoid action  
 (Kwong, Lo, 
Chow, To, et al. 
2005) 
CRBPⅣ Cellular retinol 
binding protein 4 
1p36.22 Similar to CRBP1   (Kwong, Lo, 
Chow, To, et al. 
2005) 
Tissue 
develo-
pment and 
differe-
ntiation 
Myocd Myocardin 17p11.2 Transcription factor, 
involved in smooth muscle 
cell differentiation 
 (Chen et al. 2011) 
 HIN1 
/SCGB3A1 
High-in-normal-1 5q35 Involved in epithelial cell 
differentiation, cell-cycle 
reentry regulator, 
suppresses tumor cell 
migration and invasion, 
induces apoptosis 
 
 (Wong, Kwong, 
et al. 2003) 
Others NOR1 Oxidored-nitro 
domain-contrining 
protein 1 
1p34.3 Interaction partner of the 
mitochondrial ATP 
synthase subunit 
OSCP/ATP5O protein，a 
stress-responsive gene 
 
 (Li, Li, et al. 
2011) 
 LARS2 Leucyl-tRNA 
synthetase 2, 
mitochondrial 
 
3p21.3 Essential roles in group I 
intron RNA splicing and 
protein synthesis within the 
mitochondria，indirectly 
required for mitochondrial 
genome maintenance 
 (Zhou et al. 2009) 
 CRYAB Crystallin,alpha B 11q23.1 An important nuclear role 
in maintaining genomic 
integrity 
 (Lung, Lo, 
Wong, et al. 2008) 
Table 1. List of methylated tumor suppressor genes involved in nasopharyngeal carcinoma 
(NPC) 
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3.2 Epstein-Barr virus and DNA methylation 
EBV is a prototype of gamma herpes virus which was discovered more than 40 years ago 
from Burkitt’s lymphoma, a childhood tumor that is common in sub-Saharan Africa. Further 
studies reveal that EBV was widespread in all human populations, which infects more than 
90% of the world’s adult population. Human are the only natural host for EBV. Once 
infected with EBV, the individual remains a lifelong asymptomatic carrier of the virus 
(Young and Rickinson 2004).  
EBV was implicated in a variety of human malignancies, such as post-transplant lymphoma, 
AIDS-associated lymphomas, Burkitt lymohoma, Hodgkin’s disease, T-cell lymphoma, 
NPC, parotid gland carcinoma and gastric carcinoma (Young and Rickinson 2004; Pattle and 
Farrell 2006). The association between EBV infection and NPC was well documented by the 
fact that EBV genome presents in virtually all the NPC cells (Lo and Huang 2002; Lo, To, 
and Huang 2004). Tumorigenesis of NPC is proposed to be a multistep process. EBV may 
play an important role in the etiology of the NPC, involving activation of oncogenes and/or 
the inactivation of tumor suppressor genes. Early genetic changes may predispose the 
epithelial cells to EBV infection or persistent maintenance of latent cycle. Expression of 
latent genes in the EBV-infected cells may enhance its transformation capacities, and 
subsequently, clonal expansion may result in the rapid progression to invasive carcinoma. 
There are two alternative states of EBV infection: lytic and latent (Young and Rickinson 
2004; Fernandez et al. 2009). In EBV-infected cells, virus replication with production of 
infectious virus is a rare event. Typically, EBV establishes a latent infection. This is 
characterized by the expression of a limited set of viral products, including six EBV-encoded 
nuclear antigens (EBNA1, 2, 3A, 3B, 3C, -LP), three latent membrane proteins (LMP1, 2A, 
2B) and two EBV-encoded nuclear RNAs (EBER1, EBER2). Expression of different panels of 
latent gene transcripts is controlled by usage of three distinct EBV nuclear antigen (EBNA) 
promoters (Wp, Cp, and Qp). In established lymphoblastoid cell lines (LCLs), the EBNA 
transcripts are initiated at the C promoter, Cp, located to the BamHI C fragment of the viral 
genome. In EBV genome, W promoter (Wp) is the first promoter to be activated immediately 
after EBV infection of human B cells, but it undergoes progressively methylation and 
switches off in LCLs. In parallel, an unmethylated promoter, Cp, is switched on. In other 
EBV-carrying cell types, Cp is switched off. These include memory B cells, Burkitt's 
lymphomas (BLs), EBV-associated carcinomas (NPC, gastric carcinoma) and Hodgkin's 
lymphomas; these cells typically use the Q promoter (Qp) for expression of EBNA1 
transcripts, but not the transcripts coding for the other five EBNAs, and may differ from 
each other regarding the expression of LMPs, BARTs (BARF0 and BARF1) and EBV-encoded 
microRNAs (Li and Minarovits 2003). LMP1 is the major EBV oncoprotein in NPC (Tao and 
Chan 2007; Lo, To, and Huang 2004). By activating several important cellular signalling 
pathways like NF-B, JNK, JAK/STAT and PI-3K pathway, LMP1 could upregulate anti-
apoptotic gene products, such as BCL2, A20, AP-1, CD40, CD54 and also cytokines IL-6 and 
IL-8; thereby exhibit its oncogenic characteristics (Eliopoulos and Young 2001). LMP1-
expressing NPCs show different growth pattern and prognosis from those without LMP1 
expression (Hu et al. 1995). Although EBV genome presents in virtually all the NPC cells, 
expression of LMP1 is variable in NPC: LMP1 is expressed in only approximately 65% of 
NPC biopsies (Fahraeus et al. 1988; Young et al. 1988). This variability can be related to the 
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methylation status of the regulatory sequences (LRS, LMP1 regulatory sequence) located 5’ 
from LMP1p, as LMP1 is expressed in NPCs with unmethylated LRS but is absent from 
NPCs with highly methylated LRS. A good correlation exists between LRS methylation and 
silencing of LMP1p in EBV-carrying lymphoid cell lines and tumors as well (Li and 
Minarovits 2003)). 
On the other hand, EBV regulates the expression of critical cellular genes using cellular 
DNA methylation machinery. LMP1 has been shown to interacting with methyltransferase 
and further induce the cellular gene E-cadherin (CDH1) promoter methylation. Increased 
methylation may occur through the activity of DNA methyltransferases 1, 3a, and 3b that in 
turn are induced through JNK/AP1 signalling by LMP1. Transfection of LMP1 into cancer 
cells suppressed E-cadherin expression, thereby facilitating a more invasive growth of NPC 
cells (Tsai et al. 2006). It will be interesting to discover novel target genes regulated by 
epigenetic mechanism of EBV.  
3.3 MicroRNAs in the development of NPC 
MicroRNAs (miRNAs) are short non-coding RNA molecules of about 20-23 nucleotides in 
length, involved in post-transcriptional gene regulation. In animals, miRNAs control the 
expression of target genes by inhibiting translation or degradating target mRNAs through 
binding to their 3′UTR. MicroRNAs are involved in regulating a broad range of biological 
processes, such as development, differentiation, proliferation, apoptosis, and signal 
transduction pathways often deregulated in cancers. Some miRNAs can function as tumor 
suppressors or oncogenes (McManus 2003; Ventura and Jacks 2009).  
Several biological pathways that are well characterised in cancer are significantly targeted 
by the downregulated miRNAs. These pathways include TGF-Wnt pathways, G1-S cell 
cycle progression, VEGF signalling pathways, apoptosis and survival pathways, and IP3 
signalling pathways (Chen et al. 2009). Several known oncogenic miRNAs, such as miR-141 
(Zhang et al. 2010) miR-17-92 cluster and miR-155 (Chen et al. 2009)were found to 
significantly up-regulated in NPC tumors. While some tumor suppressive miRNAs, 
including miR-34 family, miR-143, and miR-145, miR-218 (Alajez et al. 2011), mir-29c, miR-
200a, miR-26a and let-7 (Wong et al. 2011) are significantly down-regulated in NPC. Among 
them, let-7 inhibits cell proliferation through down-regulation of c-Myc expression while 
miR-26a inhibits cell growth and tumorigenesis through repression of another oncogene: 
EZH2 (Lu et al. 2011).  
EBV is reported to be present in almost all NPCs and can transform cells, which 
subsequently induces cell proliferation and tumor growth. In addition to EBV-encoded 
protein-coding genes such as EBNA1 and LMP1, NPC cells and tissues also express high 
levels of non-coding EBV RNAs, including EBER1, EBER2 and multiple microRNAs 
(miRNAs). EBV was the first human virus found to encode microRNAs (Barth, Meister, and 
Grasser 2011). By small RNA cloning and sequencing, Zhu JY et al. characterized the 
miRNA expression profile of NPC tissues. Their study revealed an NPC-specific miRNA 
signature. EBV expresses all miRNAs from the BART cluster in NPC tissues, while no 
miRNA originating from the BHRF1 region of the EBV genome was found. Their study 
suggested that BART-derived miRNAs may have an important function in maintaining the 
virus in NPC tissues, whereas BHRF1 origin miRNAs might not be required for NPC 
www.intechopen.com
 
Epigenetics of Nasopharyngeal Carcinoma 
 
15 
pathogenesis. In the same study, they also identified two novel and highly abundant EBV 
miRNA genes, namely, miR-BART21 and miR-BART22 (Zhu et al. 2009). A parallel study 
demonstrated that LMP2A is the putative target of miR-BART22 in NPC. LMP2A is a potent 
immunogenic viral antigen that is recognized by the cytotoxic T cells, down-modulation of 
LMP2A expression by miR-BART22 may permit escape of EBV-infected cells from host 
immune surveillance (Lung et al. 2009). Similar regulations were also addressed on LMP1: 
EBV-encoded BART miRNAs target the 3′ UTR of the LMP1 gene and negatively regulate 
LMP1 protein expression. These miRNAs also modulate LMP1-induced NF-κB signalling 
and alleviate the cisplatin sensitivity of LMP1-expressing NPC cells (Lo et al. 2007). 
4. Epigenetic alternations in relation to clinical parameters of NPC, and their 
roles as biomarkers 
Frequent aberrantly methylated TSGs in tumors have been used as molecular markers for 
the detection of malignant cells from various clinical materials. It provides possibilities of 
both cancer early detection and dynamic monitoring of cancer patients after treatment 
(Schulz 2005).  
DNA methylation biomarkers hold a number of advantages over other biomarker types, 
such as proteins, gene expression and DNA mutations (Balch et al. 2009; Laird 2003). 
Methylated DNA sequences are more chemically and biologically stable, and more easier to 
be amplified, thus greatly enhancing detection sensitivity. DNA methylation are often 
cancer specific, and restriction to limited regions of DNA in the CpG islands. Compared to 
genetic alternations such as gene mutation or amplification, aberrant methylation on TSG 
promoters is rather prevalent and tumor-specific among NPCs. As mentioned above, NPC 
tumor progression is well characterized by a number of combinatorial epigenetic aberrations 
distinct to other malignancy, including DNA methylation of more than 30 genes. 
Consequently, these methylated DNA sequences represent potential biomarkers for 
diagnosis, staging, prognosis and monitoring of response to therapy or tumor recurrence 
(Balch et al. 2009; Laird 2003). 
4.1 DNA methylation, results from tumor tissues 
It has been shown that some genes are high frequently methylated in tumor tissue DNA 
obtained from NPC primary tumors, but not in normal tissues (Pan et al. 2005; Sun et al. 
2007; Zhang et al. 2007; Li, Shu, et al. 2011). These genes are ideal candidate to serve as 
biomarkers for detection of NPC. Some of these TSGs are not only methylated in NPC, but 
also commonly methylated in other cancers. So methylation assessment of single genes lacks 
sufficient specificity for NPC diagnosis. It is believed that panels of multiple methylation 
biomarkers may achieve higher accuracy required for discriminate NPC from other cancers 
(Kwong et al. 2002; Hutajulu et al. 2011). This notion was supported by a study of Esteller et 
al, which showed that a panel of three to four markers could define an abnormality in 70–
90% of each cancer type through detecting their aberrant methylation (Esteller et al. 2001). 
Some studies have been conducted using different combination of gene panels, though there 
is overlap among them. Combination of methylation markers not only improved the 
discrimination between NPC and non-NPC diseases, but also the sensitivity of cancer 
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detection. The detection rate can reach 98% when combined analysis of five methylation 
markers (RASSF1A, p16, WIF1, CHFR and RIZ1) in a recent study (Hutajulu et al. 2011).  
4.2 Methylation markers in circulating DNA 
Cancer specific DNA methylation can be detected in tumor-derived free DNA in the 
bloodstream, e.g. in serum or plasma. High frequency of methylated DAPK gene were 
found not only in NPC tumors, but also could be detected in plasma and buffy coat of NPC 
patients (Wong et al. 2002). Methylated DNA was detectable in plasma of NPC patients 
before treatment including 46% for CDH1,42% for CDH1, 42% for p16, 20% for DAPK ,20% 
for p15 and 5% for RASSF1A. Aberrantly hypermethylated promoter DNA of at least one of 
the five genes was detectable in 71% of plasma of NPC patients before treatment. 
Hypermethylated promoter DNA of at least one of the three genes (CDH1, DAPK1, and p16) 
was detectable in post-treatment plasma of 38% recurrent NPC patients and none of the 
patients in remission. Suggesting that cell-free circulating methylated DNA might be a 
useful serological marker in assisting in screening of primary and potentially salvageable 
local or regional recurrent NPC (Wong et al. 2004). 
4.3 Methylation markers in other body fluids and nasopharyngeal swabs 
In addition to tissue analysis, methylated DNA has been detected in the mouth and throat 
rinsing fluid, saliva and nasopharyngeal swabs of NPC patients. Methylated DNA found in 
cancer patient serum correlated reasonably well with methylation levels in tumor tissue, 
and it is also believed that the source of serum DNA is necrotic tumor cells. 
Hypermethylated RIZ1 gene was detected in 60% of NPC primary tumors, but not in any of 
the normal controls. Of 30 matched body fluid samples, methylated RIZ1 DNA was found 
in 37% of NP swabs, 30% of rinsing fluid, 23% of plasma, and 10% of buffy coat samples. 
The results in NPC tumor and NP swab samples from the same patients show good 
concordance. Our early study also reported that the high sensitivity (81%) and specificity 
(0% false positives) of detecting aberrant methylation of CDH13 (encoded a cell adhesion 
molecule H-cadherin) from nasopharyngeal swabs suggested it could be utilized as a tool 
for early diagnosis. 
5. DNA methylation modification as therapeutic targets in NPC 
DNA methylation plays important roles in NPC carcinogenesis, including the silencing of 
cellular TSGs and some EBV encoded genes. The EBV encoded oncoprotein, LMP1, has been 
shown to interacting with methyltransferase (DNMT) and further induce the cellular gene 
E-cadherin promoter methylation (Tsai et al. 2006). And DNA methylation also suppresse 
EBV encoded genes, including the LMP1, immediate-early lytic antigens Zta and Rta, and 
some EBV immunodominant antigens (EBNA2,3A, 3B, 3C) (Paulson and Speck 1999; 
Tierney et al. 2000; Salamon et al. 2001). Thus, DNA methylation also plays an important 
role in the maintenance of specific EBV latency programmers and regulating EBV lifecycle 
and latency in NPC cells. 
DNA methylation is a reversible phenomenon. Reactivating methylated and silenced 
cellular tumor suppressor genes and immunodominant tumor/viral antigens by 
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demethylating agents might restore normal cell growth control, or induce cell immunity 
against cancer cells. Demethylating agents would also reactivate the expression of EBV early 
and lytic genes in latently infected NPC cells, which will lead to further tumor cell death.  
Epigenetic therapeutic agents include DNA methyltransferase inhibitors and histone 
deacetylase (HDAC) inhibitors. 5-Azacytidine and 5-aza-2’-deoxycytidine are the most 
widely studied DNMT inhibitors. Clinical trials using such agents have been carried out on 
a series of cancer patients. In several phase I/II/III studies, decitabine (5-aza-2’-
deoxycytidine) has also shown promising data in patients with MDS and AML (Kantarjian 
et al. 2007; Issa et al. 2004). In patients with NPC and EBV-positive AIDS-associated Burkitt 
lymphoma, azacitidine effectively induces demethylation of all the latent and early lytic 
EBV promoters and some viral antigens, indicated the potential of epigenetic therapy for 
NPC (Chan et al. 2004). 
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